Anna Cruceta

1.7k total citations
30 papers, 1.1k citations indexed

About

Anna Cruceta is a scholar working on Virology, Infectious Diseases and Emergency Medicine. According to data from OpenAlex, Anna Cruceta has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Virology, 27 papers in Infectious Diseases and 8 papers in Emergency Medicine. Recurrent topics in Anna Cruceta's work include HIV Research and Treatment (28 papers), HIV/AIDS Research and Interventions (22 papers) and HIV/AIDS drug development and treatment (19 papers). Anna Cruceta is often cited by papers focused on HIV Research and Treatment (28 papers), HIV/AIDS Research and Interventions (22 papers) and HIV/AIDS drug development and treatment (19 papers). Anna Cruceta collaborates with scholars based in Spain, United States and United Kingdom. Anna Cruceta's co-authors include José M. Gatell, Felipe García, Teresa Gallart, Tomàs Pumarola, Montserrat Plana, José M. Miró, Carmen Vidal, Giuseppe Pantaleo, Josep Mallolas and Estebán Martínez and has published in prestigious journals such as Clinical Infectious Diseases, AIDS and JAIDS Journal of Acquired Immune Deficiency Syndromes.

In The Last Decade

Anna Cruceta

30 papers receiving 1.1k citations

Peers

Countries citing papers authored by Anna Cruceta

Since Specialization

Citations

This map shows the geographic impact of Anna Cruceta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Cruceta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Cruceta more than expected).

Fields of papers citing papers by Anna Cruceta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Cruceta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Cruceta. The network helps show where Anna Cruceta may publish in the future.

Co-authorship network of co-authors of Anna Cruceta

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Cruceta. A scholar is included among the top collaborators of Anna Cruceta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Cruceta. Anna Cruceta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1–Infected Patients Starting Efavirenz, Lopinavir–Ritonavir, or Atazanavir–Ritonavir Plus Tenofovir/Emtricitabine 2015 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·José M. Miró, Christian Manzardo, Elena Ferrer, Montserrat Loncà, Alberto C. Guardo, Daniel Podzamczer, Peré Domingo, Adrián Curran, Bonaventura Clotet, Anna Cruceta, Francisco Lozano, Iñaki Pérez, Montserrat Plana, José M. Gatell	12
2	Immunological Function Restoration with Lopinavir/Ritonavir Versus Efavirenz Containing Regimens in HIV-Infected Patients: A Randomized Clinical Trial 2013 ·AIDS Research and Human Retroviruses ·Berta Torres, Norma Rallón, Montserrat Loncà, Alba Díaz, Llúcia Alós, Estebán Martínez, Anna Cruceta, Joan Albert Arnáiz, Lorna Leal, (unknown), Agathe León, Marcelo Sánchez, Eugènia Negredo, Bonaventura Clotet, José M. Gatell, José M. Benito, Felipe García	8
3	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV Type 1-Infected Patients Using a Nonnucleoside Reverse Transcriptase Inhibitor-Based or a Boosted Protease Inhibitor-Based Antiretroviral Regimen: Three-Year Results (The Advanz Trial): A Randomized, Controlled Trial 2010 ·AIDS Research and Human Retroviruses ·José M. Miró, Christian Manzardo, (unknown), Peré Domingo, Elena Ferrer, José Ramón Arribas, Esteban Ribera, Julio Arrizabalaga, Montserrat Loncà, Anna Cruceta, Elisa de Lazzari, (unknown), Daniel Podzamczer, Montserrat Plana, José M. Gatell	16
4	A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients 2007 ·Revista Clínica Española ·Josep Mallolas, (unknown), Judit Pich, Joan Albert Arnáiz, (unknown), David Dalmau, Elisa de Lazzari, Adriana Ochoa, Francesc Vidal, (unknown), F. Segura, Enric Pedrol, Juan Flores, Anna Cruceta, Sara Varea, Júlia Miró, Estebán Martínez, JM Gatell	6
5	Long-term Clinical Follow-up, without Antiretroviral Therapy, of Patients with Chronic HIV-1 Infection with Good Virological Response to Structured Treatment Interruption 2004 ·Clinical Infectious Diseases ·Éric Florence, Felipe García, Montserrat Plana, (unknown), Pedro Castro, (unknown), Anna Cruceta, (unknown), Mireia Arnedo, José M. Miró, Tomàs Pumarola, Teresa Gallart, JM Gatell	7
6	Relevance of HIV-1-Specific CD4+ Helper T-Cell Responses During Structured Treatment Interruptions in Patients With CD4+ T-Cell Nadir Above 400/mm3 2004 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Montserrat Plana, Felipe García, Annette Oxenius, Gabriel M. Ortiz, Anna Lena Lopez, Anna Cruceta, Gabriel Mestre, Emilio Fumero, Catherine Fagard, M. A. Sambeat, Ferrán Segura, José M. Miró, Mireia Arnedo, (unknown), Tomàs Pumarola, Bernard Hirschel, Rodney E. Phillips, Douglas F. Nixon, Teresa Gallart, José M. Gatell	32
7	Predictors of Tonsillar Tissue HIV-1 Viral Burden at Baseline and after 1 Year of Antiretroviral Therapy 2003 ·Antiviral Therapy ·(unknown), (unknown), Felipe García, Llúcia Alós, Mireia Arnedo, Montserrat Plana, Cristina Gil‐Sanz, Miguel Caballero, José M. Miró, Estebán Martínez, Emilio Fumero, Pedro Castro, José Luís Blanco, Josep Mallolas, José Luís Blanch, Anna Cruceta, Gabriel Mestre, Tomàs Pumarola, Teresa Gallart, José M. Gatell	8
8	Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection 2002 ·AIDS ·Felipe García, Montserrat Plana, Gabriel Mestre, Mireia Arnedo, Cristina Gil‐Sanz, José M. Miró, Anna Cruceta, Tomàs Pumarola, Teresa Gallart, José M. Gatell	14
9	The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection 2001 ·AIDS ·Felipe García, Montserrat Plana, Gabriel M. Ortiz, Sebastian Bonhoeffer, Àlex Soriano, Carmen Vidal, Anna Cruceta, Mireia Arnedo, Cristina Gil‐Sanz, Giuseppe Pantaleo, Tomàs Pumarola, Teresa Gallart, Douglas F. Nixon, José M. Miró, José M. Gatell	155
10	Predictors of progression in chronically infected naive patients with plasma viraemia below 5000 copies/ml and CD4 T lymphocytes greater than 500 × 106/l 2001 ·AIDS ·Felipe García, Montserrat Plana, Àlex Soriano, Carmen Vidal, Mireia Arnedo, Cristina Gil‐Sanz, Anna Cruceta, Tomàs Pumarola, Teresa Gallart, José M. Miró, José M. Gatell	8
11	Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy 2001 ·AIDS ·Estebán Martínez, José Luís Blanco, Juan A. Arnaiz, (unknown), Amanda Mocroft, Anna Cruceta, María Ángeles Marcos, Ana Milinkovic, Miguel A García-Viejo, Josep Mallolas, Xavier Carné, Andrew Phillips, José M. Gatell	300
12	Comparison of Immunologic Restoration and Virologic Response in Plasma, Tonsillar Tissue, and Cerebrospinal Fluid in HIV-1???Infected Patients Treated With Double Versus Triple Antiretroviral Therapy in Very Early Stages: The Spanish Earth-2 Study 2000 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·(unknown), (unknown), Joan Romeu, Hernando Knobel, Julio Arrizabalaga, Elena Ferrer, David Dalmau, Isabel Ruíz-Camps, Francesc Vidal, (unknown), Ferrán Segura, Juan Luís Gómez-Sirvent, Anna Cruceta, Bonaventura Clotet, (unknown), Teresa Gallart, William A. O’Brien, (unknown), (unknown)	14
13	Thrice-Weekly Sulfadiazine-Pyrimethamine for Maintenance Therapy of Toxoplasmic Encephalitis in HIV-Infected Patients 2000 ·European Journal of Clinical Microbiology & Infectious Diseases ·D Podzamczer, José M. Miró, Elena Ferrer, José M. Gatell, Josep Ramón, Esteban Ribera, (unknown), Anna Cruceta, Hernando Knobel, Peré Domingo, Rosa Polo, (unknown), Jaime Cosín, María Carmen Fariñas, Jon Arrizabalaga, Javier Martínez‐Sanz, Francesc Gudiol	17
14	Residual Low-Level Viral Replication Could Explain Discrepancies between Viral Load and CD4+ Cell Response in Human Immunodeficiency Virus—Infected Patients Receiving Antiretroviral Therapy 2000 ·Clinical Infectious Diseases ·Felipe García, Carmen Vidal, Montserrat Plana, Anna Cruceta, Marta Gallart, Tomàs Pumarola, José M. Miró, José M. Gatell	22
15	Dose-Finding Study of Once-Daily Indinavir/Ritonavir Plus Zidovudine and Lamivudine in HIV-Infected Patients 2000 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Josep Mallolas, José Luís Blanco, (unknown), (unknown), Estebán Martínez, Miguel A García-Viejo, Joan Albert Arnáiz, Anna Cruceta, Dolors Soy, Montserrat Tuset, Àlex Soriano, Carles Codina, Tomàs Pumarola, Xavier Carné, Josep M. Gatell	13
16	Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection 2000 ·AIDS ·Montserrat Plana, Felipe García, Teresa Gallart, Cecilia Tortajada, Àlex Soriano, Eduard Palou, María J. Maleno, (unknown), Carmen Vidal, Anna Cruceta, José M. Miró, José M. Gatell	73
17	A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study 1999 ·AIDS ·Felipe García, Joan Romeu, Inmaculada Grau, M. A. Sambeat, David Dalmau, Hernando Knobel, Juan Luís Gómez-Sirvent, Julio Arrizabalaga, Anna Cruceta, Bonaventura Clotet, Daniel Podzamczer, Tomàs Pumarola, Teresa Gallart, (unknown), José M. Miró, José M. Gatell	43
18	Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy 1999 ·AIDS ·Felipe García, Montserrat Plana, Carmen Vidal, Anna Cruceta, (unknown), Giuseppe Pantaleo, Tomàs Pumarola, Teresa Gallart, José M. Miró, José M. Gatell	215
19	Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection 1998 ·AIDS ·Carmen Vidal, Felipe García, Joan Romeu, Lidia Ruíz, José M. Miró, Anna Cruceta, Àlex Soriano, Tomàs Pumarola, Bonaventura Clotet, José M. Gatell	16
20	Predictive Factors Influencing Peak Viral Load Drop in Response to Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral-Naive HIV-1-Infected Patients 1998 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Carmen Vidal, Felipe García, José María Gatell, Manuel Leal, Bonaventura Clotet, Tomàs Pumarola, (unknown), José Mallolas, Lı́dia Ruiz, Anna Cruceta, Cecilia Tortajada	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact